29,000 delegates registered for the 70th Annual Congress of the European Society of Cardiology (26-29 August 2022) held in Barcelona, Spain, and online. Among the highlights for specialists in atherosclerosis was a state-of-the-art review of novel treatment options for hypertriglyceridaemia, latest data on the importance of cholesterol remnants, post hoc analyses from the REDUCE-IT trial, Phase 2 data on fibroblast growth factor (FGF21) analogue treatment for severe hypertriglyceridaemia and gene editing research into the inactivation of the ANGPTL3 gene.
Read the reports:
- New treatment options for hypertriglyceridaemia: Current dilemmas
- Cardiac structure and function data support need to target remnant cholesterol
- Post hoc REDUCE-IT analyses provide fresh CV insights
- ENTRIGUE: pegozafermin shows promise in severe hypertriglyceridaemia
- Cholesterol remnants and acute coronary syndrome
- CRISPR editing to inactivate ANGPTL3 gene
Reportage by Jenny Bryan
